Ultra-low-dose same-target combinations control drug resistance across stages
The emergence of drug resistance continues to limit the long term effectiveness of cancer therapies [1], as tumour cells adapt to therapeutic selective pressure through diverse genetic and non-genetic routes [2,3]. Despite advances in more potent and next generation inhibitors and mechanism based combination therapies [4,5], durable disease control remains difficult to achieve. Here we tested an…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
